The contract manufacturing market for live biotherapeutics and microbiome products :::

Roots Analysis has done a detailed study on Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 300+ page report, which features 140+ figures and 125+ tables, please visit this link 
Key Market Insights 
  • The microbiome therapies pipeline features 260 drugs under evaluation across different phases of development; contract service providers have become an integral part of the supply chain owing to their technical expertise.
  • Presently, over 25 firms across the globe claim to possess the required know-how and infrastructure to offer contract manufacturing services for live biotherapeutic products and microbiome therapies
  • The market is fragmented, featuring the presence of established players and mid-sized firms across different global regions, with capabilities to manufacture aerobic and / or anaerobic strains, at varying scales of operation
  • Most of the installed, global live biotherapeutic contract manufacturing capacity presently belongs to dedicated large and mid-sized CMOs, accounting for over 90% of what is available across various geographies
  • Future growth of the market is likely to be driven by increased demand for these therapeutics; we expect the service-based revenues to grow at an annualized rate of over 46% in the coming decade
  • In the long-term, the projected market opportunity is anticipated to be well distributed across different types of formulations, sizes of contract service providers and geographical regions
For more information, please visit https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html
 
Table of Contents
1.         PREFACE
1.1.       Scope of the Report
1.2.       Research Methodology
1.3.       Chapter Outlines
2.         EXECUTIVE SUMMARY
3.         INTRODUCTION
3.1.       Chapter Overview
3.2.       Concept of Human Microbiota and Microbiome
3.3.       Overview of Gut Flora
3.2.3.    Role of Gut Flora in Healthy Individuals
3.2.4.    Factors Affecting Human Gut Flora
3.4.       The Human Microbiome Project (HMP)
3.5.       Overview of Microbiome Therapies
3.5.1.    Types of Microbiome Therapies
3.5.1.1. Probiotics
3.5.1.2. Prebiotics
3.5.2.    Applications of Microbiome Therapies
3.5.3.    Microbiome Therapies Supply Chain
3.6.       Microbiome-based Product Manufacturing
3.6.1.    Key Steps Involved
3.6.2.    Associated Challenges
3.6.3.    Role of Contract Manufacturing Organizations (CMOs)
3.6.4.    Demand for Contract Manufacturing Services
3.7.       Key Considerations for Selecting a Suitable CMO Partner
4.         MARKET LANDSCAPE
4.1.       Chapter Overview
4.2.       CMOs Offering Contract Manufacturing for Microbiome Therapeutics: List of Companies
4.2.1.    Analysis by Year of Establishment
4.2.2.    Analysis by Company Size
4.2.3.    Analysis by Scale of Operation
4.2.4.    Analysis by Location of Headquarters
4.2.5.    Analysis by Type of Service Offered
4.2.6.    Analysis by Type of Product Manufactured
4.2.7.    Analysis by Type of Drug Molecule
4.2.8.    Analysis by Type of Fermentation Required
4.2.9.    Analysis by Type of Formulation
4.2.10.  Analysis by Type of Primary Packaging Used
4.2.11. Analysis by Number of Manufacturing Facilities
4.2.12. Analysis by Location of Manufacturing Facilities
4.2.13. Analysis by Type of Regulatory Certifications / Accreditations
4.3.       Microbiome Therapeutics In-House Manufacturers: List of Companies
4.3.1.    Analysis by Year of Establishment
4.3.2.    Analysis by Company Size
4.3.3.    Analysis by Scale of Operation
4.3.4.    Analysis by Location of Headquarters
4.3.5.    Analysis by Location of Manufacturing Facilities
5.         COMPANY PROFILES
5.1.       Chapter Overview
5.2.       CMOs Headquartered in North America
5.2.1.    Capsugel
5.2.1.1. Company Overview
5.2.1.2. Microbiome-Related Service Portfolio
5.2.1.3. Facilities Dedicated to Microbiome Manufacturing
5.2.1.4. Recent Developments and Future Outlook
5.2.2.    Paragon Bioservices
5.2.2.1. Company Overview
5.2.2.2. Microbiome-Related Service Portfolio
5.2.2.3. Facilities Dedicated to Microbiome Manufacturing
5.2.2.4. Recent Developments and Future Outlook
5.2.3.    UAS Labs
5.2.3.1. Company Overview
5.2.3.2. Microbiome-Related Service Portfolio
5.2.3.3. Facilities Dedicated to Microbiome Manufacturing
5.2.3.4. Recent Developments and Future Outlook
5.3.       CMOs Headquartered in Europe
5.3.1.    Biose
5.3.1.1. Company Overview
5.3.1.2. Microbiome-Related Service Portfolio
5.3.1.3. Facilities Dedicated to Microbiome Manufacturing
5.3.1.4. Recent Developments and Future Outlook
5.3.2.    Cobra Biologics
5.3.2.1. Company Overview
5.3.2.2. Financial Information
5.3.2.3. Microbiome-Related Service Portfolio
5.3.2.4. Facilities Dedicated to Microbiome Manufacturing
5.3.2.5. Recent Developments and Future Outlook
5.3.3.    Cerbios
5.3.3.1. Company Overview
5.3.3.2. Microbiome-Related Service Portfolio
5.3.3.3. Facilities Dedicated to Microbiome Manufacturing
5.3.3.4. Recent Developments and Future Outlook
5.3.4.    Inpac Probiotics
5.3.4.1. Company Overview
5.3.4.2. Microbiome-Related Service Portfolio
5.3.4.3. Facilities Dedicated to Microbiome Manufacturing
5.4.       CMOs Headquartered in Asia-Pacific and Rest of the World
5.4.1.    BJP Laboratories
5.4.1.1. Company Overview
5.4.1.2. Microbiome-Related Service Portfolio
5.4.1.3. Facilities Dedicated to Microbiome Manufacturing
6.         REGIONAL CAPABILITY ANALYSIS
6.1.       Chapter Overview
6.2.       Key Assumptions and Methodology
6.3.       Regional Capability Analysis: Microbiome Contract Manufacturers in North America
6.4.       Regional Capability Analysis: Microbiome Contract Manufacturers in Europe
6.5.       Regional Capability Analysis: Microbiome Contract Manufacturers in Asia-Pacific and Rest of the World
6.6.       Concluding Remarks
                       
7.         LIKELY PARTNER ANALYSIS
7.1.       Chapter Overview
7.2.       Scope and Methodology
7.3.       Potential Strategic Partners for Microbiome Contract Manufacturers
7.3.1.    Opportunities in North America
7.3.2.    Opportunities in Europe and Asia-Pacific
8.         CLINICAL TRIAL ANALYSIS
8.1.       Chapter Overview
8.2.       Scope and Methodology
8.3.       Clinical Trial Analysis (Industry Players)
8.3.1.    Analysis by Trial Registration Year
8.3.2.    Analysis by Trial Phase
8.3.3.    Analysis by Trial Recruitment Status
8.3.4.    Analysis by Trial Registration Year and Recruitment Status
8.3.5.    Analysis by Trial Registration Year and Number of Patients Enrolled
8.3.6.    Analysis by Study Design
8.3.7.    Analysis by Trial Focus
8.3.8.    Analysis by Trial Phase and Type of Intervention Model
8.3.9.    Analysis by Sponsor / Collaborator
8.3.10. Analysis by Type of Organization
8.3.11.  Popular Therapeutic Areas: Analysis by Number of Clinical Trials and Registration Year
8.3.12. Geographical Analysis by Number of Clinical Trials
8.3.13.  Geographical Analysis by Trial Recruitment Status
8.4.       Clinical Trial Analysis (Non-Industry Players)
8.4.1.    Analysis by Trial Registration Year
8.4.2.    Analysis by Trial Phase
8.4.3.    Analysis by Trial Recruitment Status
8.4.4.    Analysis by Trial Registration Year and Recruitment Status
8.4.5.    Analysis by Trial Registration Year and Number of Patients Enrolled
8.4.6.    Analysis by Study Design
8.4.7.    Analysis by Trial Focus
8.4.8.    Analysis by Trial Phase and Type of Intervention Model
8.4.9.    Analysis by Sponsor / Collaborator
8.4.10. Analysis by Type of Organization
8.4.11.  Popular Therapeutic Areas: Analysis by Number of Clinical Trials and Registration Year
8.4.12. Geographical Analysis by Number of Clinical Trials
8.4.13.  Geographical Analysis by Trial Recruitment Status
9.         CAPACITY ANALYSIS
9.1.       Chapter Overview
9.2.       Key Assumptions and Methodology
9.3.       Microbiome Contract Manufacturers: Global Production Capacity
9.3.1.    Analysis by Company Size
9.3.1.1. Overall Production Capacity of Small-sized Companies 
9.3.1.2. Overall Production Capacity of Mid-sized Companies
9.3.1.3. Overall Production Capacity of Large Companies
9.3.2.    Analysis by Scale of Operation
9.3.2.1. Overall Clinical Scale Production Capacity
9.3.2.2. Overall Commercial Scale Production Capacity
9.3.3.    Analysis by Location of Manufacturing Facility
9.3.3.1. Overall Production Capacity in North America
9.3.3.2. Overall Production Capacity in Europe
9.3.3.3. Overall Production Capacity in Asia-Pacific and Rest of the World
9.4.       Concluding Remarks
10.        DEMAND ANALYSIS
10.1.     Chapter Overview
10.2.     Scope and Methodology
10.3.     Global Clinical Demand for Microbiome Contract Manufacturing
10.3.1. Geographical Analysis of Demand
10.3.1.1. Clinical Demand in North America
10.3.1.2. Clinical Demand in Europe
10.3.1.3. Clinical Demand in Asia-Pacific and Rest of the World
10.3.2. Phase-Wise Analysis of Demand
10.3.2.1. Clinical Demand in Phase I
10.3.2.2. Clinical Demand in Phase II
10.3.2.3. Clinical Demand in Phase III
10.3.3. Sponsor Wise Analysis of Demand
10.3.2.1. Clinical Demand for Industry Sponsors
10.3.2.2. Clinical Demand for Non-Industry Sponsors
10.4      Concluding Remarks
11.        MAKE VERSUS BUY DECISION MAKING FRAMEWORK
11.1.     Chapter Overview
11.2.     Make versus Buy Decision Making: Assumptions and Parameter Definitions
11.2.1.  Scenario 1: High Value Addition / Low Complexity
11.2.1.  Scenario 2: High Value Addition / High Complexity
11.2.1.  Scenario 3: Low Value Addition / Low Complexity
11.2.1.  Scenario 4: Low Value Addition / High Complexity
11.3.     Contract Manufacturer’s Perspective
11.4.     Concluding Remarks
12.        MICROBIOME RELATED INITIATIVES OF BIG PHARMACEUTICAL PLAYERS
12.1.     Chapter Overview
12.2.     Scope and Methodology
12.3.     Initiatives of Big Pharmaceutical Players
12.3.1.  Analysis by Portfolio Diversity
12.3.2.  Analysis by Phase of Development
12.3.3. Analysis by Type of Therapeutic
12.3.4. Analysis by Type of Drug Molecule
12.3.5. Heat Map: Analysis by Target Therapeutic Areas
12.4.     Benchmark Analysis of Big Pharmaceutical Players
12.4.1. Spider Web Analysis: Company A
12.4.2. Spider Web Analysis: Company B
12.4.3. Spider Web Analysis: Company C
12.4.4.  Spider Web Analysis: Company D
12.4.5. Spider Web Analysis: Company E
12.4.6. Spider Web Analysis: Company F
12.4.7. Spider Web Analysis: Company G
12.4.8. Spider Web Analysis: Company H
12.4.9. Spider Web Analysis: Company I
12.4.10. Spider Web Analysis: Company J
12.4.11. Spider Web Analysis: Company K
12.5.     Concluding Remarks
13.        MARKET FORECAST
13.1.     Chapter Overview
13.2.     Forecast Methodology and Key Assumptions
13.3.     Overall Microbiome Contract Manufacturing Market, 2020-2030
13.4      Microbiome Contract Manufacturing Market, 2020-2030: Distribution by Product Manufactured
13.4.1.  Microbiome Contract Manufacturing Market for APIs, 2020-2030
13.4.2.  Microbiome Contract Manufacturing Market for FDFs, 2020-2030
13.5.     Microbiome Contract Manufacturing Market, 2020-2030: Distribution by Type of Formulation
13.5.1.  Microbiome Contract Manufacturing Market for Solid Formulations, 2020-2030
13.5.2.  Microbiome Contract Manufacturing Market for Oral Liquids, 2020-2030
13.5.3.  Microbiome Contract Manufacturing Market for Injectables, 2020-2030
13.5.4.  Microbiome Contract Manufacturing Market for Others, 2020-2030
13.6.     Microbiome Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation
13.6.1.  Microbiome Contract Manufacturing Market for Clinical Scale Operations, 2020-2030
13.6.2.  Microbiome Contract Manufacturing Market for Commercial Scale Operations, 2020-2030
13.7.     Microbiome Contract Manufacturing Market, 2020-2030: Distribution by Company Size
13.7.1.  Microbiome Contract Manufacturing Market for Small-sized Companies, 2020-2030
13.7.2.  Microbiome Contract Manufacturing Market for Mid-sized Companies, 2020-2030
13.7.3.  Microbiome Contract Manufacturing Market for Large Companies, 2020-2030
13.8.     Microbiome Contract Manufacturing Market, 2020-2030: Geographical Distribution
13.8.1.  Microbiome Contract Manufacturing Market in North America, 2020-2030
13.8.2. Microbiome Contract Manufacturing Market in Europe, 2020-2030
13.8.3. Microbiome Contract Manufacturing Market in Asia-Pacific and Rest of the World, 2020-2030
13.9.     Concluding Remarks
14.        CONCLUSION
14.1.     Chapter Overview
14.2.     Key Takeaways
15.        EXECUTIVE INSIGHTS
15.1.     Chapter Overview
15.2.     S-Biomedic
15.2.1.  Company Snapshot
15.2.2.  Interview Transcript: Veronika Oudova, Co-founder and Chief Executive Officer
15.3.     Meteoric Biopharmaceuticals
15.3.1.  Company Snapshot
15.3.2.  Interview Transcript: Gaurav Kaushik, Managing Director and Chief Executive Officer
15.4.     BiomX
15.4.1.  Company Snapshot
15.4.2.  Interview Transcript: Assaf Oron, Chief Business Officer
15.5.     Universal Stabilization Technologies
15.5.1   Company Snapshot
15.5.2.  Interview Transcript: Alexander Segal, Vice President, Business Development
15.6.     List Biological Laboratories
15.6.1.  Company Snapshot
15.6.2.  Interview Transcript: Debbie Pinkston, Vice President, Sales and Business Development
15.7.     Assembly Biosciences
15.7.1.  Company Snapshot
15.7.2.  Interview Transcript: JP Benya, Vice President, Business Development
15.8.     Wacker Biotech
15.8.1   Company Snapshot
15.8.2.  Interview Transcript: Rob van Dijk, Business Development Manager
15.9.     Chung Mei Pharmaceutical
15.9.1.  Company Snapshot
15.9.2.  Interview Transcript: Alexander Lin, Associate General Manager
16.        APPENDIX I: TABULATED DATA
 
17.        APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
 
18.        APPENDIX III: LIST OF PROBIOTIC SUPPLEMENT CONTRACT MANUFACTURERS AND MICROBIAL CONTACT SERVICE PROVIDERS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
 [email protected]

You may also like

Discussion

No comments yet... Be the first to leave a reply! Login here

avatar
BenJ
0 Karma
781 Posts

Made with by Mamby